T-cell Biofactories for targeting interstitial fluid pressure

Year of Award:
Award Type:
Project Number:
RFA Number:
Technology Track:
Molecular & Cellular Analysis Technologies
PI/Project Leader:
Other PI or Project Leader:
Not Applicable
PROJECT SUMMARY The focus of this proposal is to develop pressure-sensitive T cells that can activate in response to the highinterstitial fluid pressure (IFP) in many solid tumors and release an engineered enzyme to neutralize its source.The dense fibrous extracellular matrix (ECM) tissue growth common in many solid tumors presents a physicalbarrier to the current standard of care chemotherapies and immunotherapies. It leads to the compressivestresses that cause high interstitial fluid pressure (IFP) (>100 mmHg) as compared to that within normaltissues (-4 to -6 mmHg). Together, the ECM barrier and IFP resist the influx of therapeutics into tumor sites.The ECM also harbors the tumor microenvironment (TME) that causes drug resistance andimmunosuppression. Hence, the challenge is to selectively break down the ECM at the tumor site to enable theentry of therapeutic cytolytic T cells without affecting the normal connective tissues. Here, the investigatorspropose that T cells can be engineered to provide a solution to this challenge by selectively degrading theECM. The investigators' long-term goal is to develop new treatments by harnessing the cell's potential tointeract with the in vivo environment and target the underlying mechanisms in the disease pathology. Theobjective of this project, toward this long-term goal, is to engineer the T cells to synthesize and release theECM degrading enzymes upon sensing increased IFP. To achieve this objective, their strategy is to engineerthe T cells with an artificial cell signaling cascade that upregulates the desired proteins in situ. This work issupported by their preliminary work on engineering the T cells and use of a new assay to simulate IFP in vitro.The rationale for this effort is that it will lead to a cellular technology to locally disrupt the tumor ECM andreduce IFP to assist the influx of antitumor agents for improved treatment outcome. The investigators havedescribed specific milestones with quantitative metric of success and will use the following parallel aims toconduct the investigations: Engineering of T cells with pressure-sensitive trigger (Aim 1); Engineering of T cellfor pressure-induced expression of ECM degrading enzyme (Aim 2). This effort is expected to lead to a broad-spectrum technology that has the potential for high-impact. This is because there is no known molecularbiomarker to target either the ECM or IFP. The proposed approach is innovative because it challenges thestatus quo by engineering the T cells to actively traffic to the TME and synthesize an ECM-degrading enzymein situ. This will mitigate the IFP and enable perfusion of engineered cytolytic T cells to kill tumor cells; as wellas alter the continuously evolving TME to overcome drug resistance and immunosuppression.